Determination of a Sample-to-Cutoff Ratio to Predict True-Positivity in Blood Donor Samples Screened for Syphilis by a Chemiluminescent Immunoassay
Determination of a Sample-to-Cutoff Ratio to Predict True-Positivity in Blood Donor Samples Screened for Syphilis by a Chemiluminescent Immunoassay
Purpose: The use of Architect Syphilis TP (CMIA) in the blood bank raised the number of syphilis positive samples requiring confirmation. Theaim of this study is to determine a sample-to-cutoff (s/co) ratio for CMIA predicting ≥95% of true-positive samples to reduce these samples.Methods: CMIA reactive samples (n=177) were evaluated by Western blot (WB) as the reference standard, as well as by Treponema pallidumhemagglutination (TPHA) and Rapid Plasma Reagin (RPR) tests. The s/co ratio predicting ≥95% of true-positive samples was defined as thethreshold leaving ≥95% of WB confirmed samples greater than the particular value. The performances of TPHA and RPR tests were alsoevaluated with respect to s/co ratios of CMIA positive samples.Results: The s/co ratio 15.17 predicted a true-positive result for ≥95% of samples tested (95% confidence interval: 85.9–99.3) and reduced thenumber of samples requiring confirmation by 29.9%. Higher s/co ratios were correlated with the increasing number of bands on WB strips(p95% of positive samples with s/co ratios ≥15, its sensitivity was 47.7%.Conclusion: Higher s/co ratios can be used to define true-positivity and may indicate an active infection. TPHA may replace WB to confirmsamples with s/co ratios between 3 and 15. RPR should not be used as a screening test in blood banks as it could miss almost half of the truepositive samples.
___
- World Health Organization. Department of HIV/AIDS. Global
prevalence and incidence of selected curable sexually transmitted
infections: overview and estimates. Geneva, Switzerland: WHO;
2001. Available from: http://www.who.int/reproductivehealth/
publications/rtis/HIV_AIDS_2001_2/en/ Accessed: November 29,
2017.
- World Health Organization. Screening donated blood for transfusiontransmissible infections: recommendations. Geneva, Switzerland:
WHO; 2009. Available from: http://www.who.int/bloodsafety/
ScreeningTTI.pdf Accessed: November 29, 2017.
- Centers for Disease Control and Prevention. Syphilis testing algorithms
using treponemal tests for initial screening –four laboratories, New York
City, 2005–2006. MMWR Morb Mortal Wkly Rep 2008;57:872–875.
- French P, Gomberg M, Janier M, et al. IUSTI: 2008 European Guidelines
on the Management of Syphilis. Int J STD AIDS 2009;20:300–309.
[CrossRef]
- de Lemos EA, Belém ZR, Santos A, Ferreira AW. Characterization of
the Western blotting IgG reactivity patterns in the clinical phases
of acquired syphilis. Diagn Microbiol Infect Dis 2007;58:177–183.
[CrossRef]
- Wang LN, Li JM. Evaluation of immunoglobulin M and G Western
blot and ELISA for screening antibodies to Treponema pallidum in
blood donors. Sex Transm Dis 2009;36:413–416. [CrossRef]
- Welch RJ, Litwin CM. Evaluation of two immunoblot assays and a
Western blot assay for the detection of antisyphilis immunoglobulin
g antibodies. Clin Vaccine Immunol 2010;17:183–184. [CrossRef]
- Backhouse JL, Nesteroff SI. Treponema pallidum western blot:
comparison with the FTA-ABS test as a confirmatory test for syphilis.
Diagn Microbiol Infect Dis 2001;39:9–14.
- Young H, Pryde J, Duncan L, Dave J. The Architect Syphilis assay
for antibodies to Treponema pallidum: an automated screening
assay with high sensitivity in primary syphilis. Sex Transm Infect
2009;85:19–23. [CrossRef]
- Marangoni A, Moroni A, Accardo S, Cevenini R. Laboratory diagnosis
of syphilis with automated immunoassays. J Clin Lab Anal 2009;23:1–
6. [CrossRef]
- Alter MJ, Kuhnert WL, Finelli L; Centers for Disease Control and
Prevention. Guidelines for laboratory testing and results reporting
of antibody to hepatitis C virus. Centers for Disease Control and
Prevention. MMWR Recomm Rep 2003;52:1–15.
- Kiely P, Walker K, Parker S, Cheng A. Analysis of sample-to-cutoff
ratios on chemiluminescent immunoassays used for blood donor
screening highlights the need for serologic confirmatory testing.
Transfusion 2010;50:1344–1351. [CrossRef]
- Oncul O, Emekdas G, Cavuslu S, Artuk C, Aksoy A. The sixteenyear trend of syphilis in Turkey: data from blood donors. Trop Doct
2008;38:181–182. [CrossRef]
- Kocak N, Hepgul S, Ozbayburtlu S, et al. Trends in major transfusiontransmissible infections among blood donors over 17 years in
Istanbul, Turkey. J Int Med Res 2004;32:671–675. [CrossRef]
- Gok G, Yurdakul B, Dundar IH, et al. Evaluation of Turkish Red
Crescent Aegean Regional Blood Bank donor screening results.
Proceeding of the Second National Blood Centers and Transfusion
Medicine Congress; 2007 Nov 15–19 Antalya, Turkey. p.206–261.
- McGill MA, Edmondson DG, Carroll JA, Cook RG, Orkiszewski RS,
Norris SJ. Characterization and serologic analysis of the Treponema
pallidum proteome. Infect Immun 2010;78:2631–2643. [CrossRef]
- Kingston M, French P, Goh B, et al.; Syphilis Guidelines Revision
Group 2008, Clinical Effectiveness Group. UK National Guidelines on
the Management of Syphilis 2008. Int J STD AIDS 2008;19:729–740.
[CrossRef]
- Maple PA, Ratcliffe D, Smit E. Characterization of Treponema pallidum
particle agglutination assay-negative sera following screening by
treponemal total antibody enzyme immunoassays. Clin Vaccine
Immunol 2010;17:1718–1722. [CrossRef]
- Sánchez PJ, Wendel GD Jr, Grimprel E, et al. Evaluation of molecular
methodologies and rabbit infectivity testing for the diagnosis of
congenital syphilis and neonatal central nervous system invasion by
Treponema pallidum. J Infect Dis 1993;167:148–157.
- McKevitt M, Brinkman MB, McLoughlin M, et al. Genome scale
identification of Treponema pallidum antigens. Infect Immun
2005;73:4445–4450. [CrossRef]
- Brinkman MB, McKevitt M, McLoughlin M, et al. Reactivity of
antibodies from syphilis patients to a protein array representing the
Treponema pallidum proteome. J Clin Microbiol 2006;44:888–891.
[CrossRef]